Dr Khitam Muhsen and colleagues from Israel conducted an updated systematic review and meta-analysis to examine the prevalence of depleted iron stores among persons infected with Helicobacter pylori compared to uninfected ones.
The researchers also assessed the impact of anti-Helicobacter pylori eradication therapy plus iron therapy on ferritin and hemoglobin levels compared to iron therapy alone.
The team conducted a literature search using the databases Medline, the Cochrane Library, Cochrane Central Register of Controlled Trials, EMBASE, and the Science Citation Index Expanded.
|Helicobacter pylori-infected individuals showed increased likelihood of iron deficiency anemia|
Observational studies with methodological quality score of 13 and above, on a scale of 0–16, and all randomized controlled trials were eligible for the meta-analyses.
Compared to uninfected persons, Helicobacter pylori-infected individuals showed increased likelihood of iron deficiency anemia, iron deficiency, and anemia.
The research team found that meta-analyses of 7 randomized controlled trials showed increased ferritin, but not hemoglobin, following anti-Helicobacter pylori eradication therapy plus iron therapy as compared with iron therapy alone.
Significant heterogeneity was found among studies, as well as evidence of publication bias.
Dr Muhsen's team comments, "Current evidence indicates increased likelihood of depleted iron stores in relation to Helicobacter pylori infection."
"Helicobacter pylori eradication therapy, added to iron therapy, might be beneficial in increasing ferritin and hemoglobin levels."